HC Wainwright Predicts Precigen’s Q1 Earnings (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) – HC Wainwright issued their Q1 2026 earnings estimates for Precigen in a research report issued to clients and investors on Monday, July 14th. HC Wainwright analyst S. Ramakanth expects that the biotechnology company will earn ($0.02) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at $0.02 EPS.

Several other equities analysts also recently issued reports on the stock. Wall Street Zen raised shares of Precigen from a “sell” rating to a “hold” rating in a report on Saturday. JMP Securities reiterated a “market outperform” rating and issued a $6.00 price objective on shares of Precigen in a research report on Thursday, June 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Precigen in a research report on Thursday, May 15th.

Precigen Price Performance

Shares of PGEN opened at $1.85 on Tuesday. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17. The stock has a fifty day moving average price of $1.48 and a 200 day moving average price of $1.50. The company has a market cap of $546.08 million, a P/E ratio of -3.30 and a beta of 1.78.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. The business had revenue of $1.34 million for the quarter, compared to analysts’ expectations of $0.50 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its stake in shares of Precigen by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 56,012 shares in the last quarter. CIBC Private Wealth Group LLC increased its stake in Precigen by 29.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 331,476 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 74,422 shares during the period. Geode Capital Management LLC raised its position in shares of Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after buying an additional 53,343 shares in the last quarter. RPO LLC bought a new stake in shares of Precigen during the 4th quarter worth about $47,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Precigen by 12.0% in the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 12,285 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.